HER2-Targeted Therapy Gains Ground in Metastatic Colorectal Cancer with New Treatment Sequencing Guidance

▸ TREATMENT

Narrative review outlines practical patient selection and treatment sequencing for HER2-targeted therapies in metastatic colorectal cancer, focusing on RAS wild-type disease with HER2 overexpression or ERBB2 amplification, including dual HER2 blockade and antibody-drug conjugates like trastuzumab deruxtecan. (Journal of Gastrointestinal Cancer)